Werewolf Therapeutics Q2 net loss $14.6M; FDA clears IND for WTX-124; $145.7M cash runway through Q4 2023

Werewolf Therapeutics, Inc.

2022-Q2 EPS reported -$1.09

Net loss of $14.6M in Q2 2022, vs $10.9M in Q2 2021; R&D expenses rose to $13.9M.
FDA cleared IND for WTX-124 (IL-2 INDUKINE) for advanced solid tumors; Phase 1/1b trial to start.
IND application for WTX-330 (IL-12 INDUKINE) planned in 2H22.
Cash and equivalents $145.7M as of June 30, 2022, vs $157.5M at Dec 31, 2021.
Collaboration revenue from Jazz deal $4.1M in Q2; Jazz upfront payment $15M, potential milestones up to $1.26B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.